The BioFocus website uses cookies to store information on your computer, to improve our website. One of the cookies we use is essential for parts of the site to operate and has already been set. You may delete and block all cookies from this site, but parts of the site will not work. To find out more about the cookies we use and how to delete them, see our privacy notice.


I accept cookies from this site
 

In this section

Filter by year:

Events


Newsletters

Get in contact with us








Back

News & events

BioFocus launches new compound libraries

Fri 24 Sep 2010
BioFocus launches new compound libraries

BioFocus, a leading provider of integrated gene-to-clinical candidate drug discovery services, today announced the launch of two new compound libraries, targeting Family C GPCR’s and protein-protein interactions.

BioFocus’ new protein-protein interaction library (PPI01) is designed around a novel scaffold that mimics a “beta-sheet type” hydrogen bonding pattern, a key motif observed in protein-protein interactions.  The new FieldFocus GPCR library (FFG01) is designed using field- and shape-based overlays of known ligands to generate a novel library that targets the allosteric site of metabotropic glutamate receptors, a subtype of Family C GPCRs.

“These latest libraries target areas that are of specific interest to the drug discovery community” said Richard Gordon, Senior Director, Sales and Marketing BioFocus. “In the past 10 years we have expanded our range of available libraries from kinase and GPCR focused, to those targeting ion channels, nucleosides and proteases, and most recently a series targeting protein-protein interactions, providing a level of success of which we are extremely proud.”  

About SoftFocus libraries

For the past 10 years, BioFocus has pioneered the field of rationally designed focused libraries through its SoftFocus brand. The novel libraries, designed to target specific gene families, have proved immensely valuable to clients, generating potent and selective molecules at higher rates than other collections. This success has been shown through numerous client publications and patents, with several clinical candidates directly derived from compounds within the SoftFocus range.

About BioFocus

BioFocus aims to expand its partners’ drug pipelines by accelerating the gene-to-clinical candidate discovery process.  This is achieved through a comprehensive discovery platform, which includes target discovery in human primary cells, focused as well as diverse compound libraries, in vitro and cell-based screening, structural biology, medicinal chemistry, ADME/PK services, supported by unique chemogenomic and informatics tools, and compound library acquisition, storage and distribution services.  As a service division of Galapagos, BioFocus has over 250 employees in three countries worldwide. 






Print to HTML Print as PDF Send to a friend




BioFocus®, SoftFocus®, Galapagos®, SilenceSelect® and FLeXSelect® ThemePair™, FieldFocus™, HDRA™. Helical Domain Recognition Analysis™, 2D Roadmap™, Thematic Analysis™, SFK™, SFI™, SFG™ and PrimePath™ are trademarks of Galapagos NV and/or its affiliates.